Ironwood Pharmaceuticals (IRWD) adds 10M shares to 2019 equity incentive plan
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Ironwood Pharmaceuticals, Inc. reported that stockholders approved an amendment to its Amended and Restated 2019 Equity Incentive Plan at the 2026 Annual Meeting of Stockholders. The amendment increases the number of shares of Class A common stock available for issuance under the plan by 10,000,000 shares, expanding the pool for future equity-based compensation grants.
Stockholders also voted on the election of directors and other proposals, with each director nominee receiving over 104 million votes in favor and substantial broker non-votes recorded. Additional proposals received support levels including 104,461,936 votes for one item and 121,957,895 votes for another, indicating strong overall approval.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 5.07, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Equity plan share increase: 10,000,000 shares
Votes for director nominee (example): 107,222,711 votes
Broker non-votes (director elections): 15,446,984 votes
+2 more
5 metrics
Equity plan share increase
10,000,000 shares
Additional Class A common stock available under Amended 2019 Equity Incentive Plan
Votes for director nominee (example)
107,222,711 votes
For Mark Currie, Ph.D., director election at 2026 Annual Meeting
Broker non-votes (director elections)
15,446,984 votes
Broker non-votes reported for each director nominee
Proposal support level (example)
104,461,936 votes for
For one non-director proposal at 2026 Annual Meeting
Highest proposal support
121,957,895 votes for
For another proposal at 2026 Annual Meeting
Key Terms
Annual Meeting of Stockholders, Amended and Restated 2019 Equity Incentive Plan, Broker Non-Votes, Definitive Proxy Statement on Schedule 14A, +2 more
6 terms
Annual Meeting of Stockholders financial
"held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)."
Amended and Restated 2019 Equity Incentive Plan financial
"to the Company’s Amended and Restated 2019 Equity Incentive Plan (the “Plan”"
Broker Non-Votes financial
"For | | Against | | Abstain | | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
Definitive Proxy Statement on Schedule 14A regulatory
"described on pages 53 to 58 in the Company’s Definitive Proxy Statement on Schedule 14A"
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Section 13 or 15(d) of the Securities Exchange Act of 1934 regulatory
"Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934"
FAQ
What equity plan change did Ironwood Pharmaceuticals (IRWD) stockholders approve?
Stockholders approved an amendment to Ironwood’s Amended and Restated 2019 Equity Incentive Plan, increasing the shares available for issuance by 10,000,000 Class A common shares. This larger pool supports future equity-based awards to directors, officers, and employees under the company’s incentive plan.
When did Ironwood Pharmaceuticals (IRWD) hold its 2026 Annual Meeting?
Ironwood Pharmaceuticals held its 2026 Annual Meeting of Stockholders on June 16, 2026. At this meeting, investors voted on director elections, the amendment to the 2019 Equity Incentive Plan, and other proposals, with detailed final voting results reported in the Form 8-K filing.
How strong was support for Ironwood Pharmaceuticals’ proposals at the 2026 meeting?
Support was high across proposals, including 121,957,895 votes for one item and over 104 million votes for others, with relatively low against and abstain tallies. Director nominees each received more than 104 million votes for, alongside notable broker non-votes on certain items.
Where can investors find full details of Ironwood’s amended equity plan?
Full details of the amended plan are in Ironwood’s Definitive Proxy Statement on Schedule 14A, pages 53–58, filed April 28, 2026, and in Exhibit 10.1 to this Form 8-K, which contains the complete text of Amendment No. 1 to the 2019 Equity Incentive Plan.